NASDAQ:AGIO
Agios Pharmaceuticals Stock News
$33.88
+0.690 (+2.08%)
At Close: May 21, 2024
Is Agios Pharmaceuticals Inc.s (NASDAQ: AGIO) -6.10% Loss This Week Telling Us Something New?
03:30pm, Thursday, 25'th Nov 2021 Marketing Sentinel
During the last session, Agios Pharmaceuticals Inc. (NASDAQ:AGIO)s traded shares were 0.56 million, with the beta value of the company hitting 1.47. At the end of the trading day, the stocks price was $37.25, reflecting an intraday loss of -0.32% or -$0.12. The 52-week high for the AGIO share is $62.15, that puts it down Is Agios Pharmaceuticals Inc.s (NASDAQ: AGIO) -6.10% Loss This Week Telling Us Something New? Read More »
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Position Decreased by Harbor Investment Advisory LLC
01:32pm, Monday, 22'nd Nov 2021 Dakota Financial News
Harbor Investment Advisory LLC cut its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 83.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 924 shares of the biopharmaceutical companys stock after selling 4,607 shares during the period. Harbor Investment Advisory []
Agios Pharmaceuticals (NASDAQ:AGIO) PT Lowered to $42.00
09:32am, Saturday, 20'th Nov 2021 Dakota Financial News
Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective reduced by research analysts at SVB Leerink from $50.00 to $42.00 in a research note issued to investors on Thursday, Analyst Price Targets reports. The firm currently has a market perform rating on the biopharmaceutical companys stock. SVB Leerinks target price would suggest a potential upside of 9.89% []
Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3
02:33pm, Wednesday, 03'rd Nov 2021
Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.
Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call Transcript
12:45pm, Wednesday, 03'rd Nov 2021
Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call Transcript
Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
04:01pm, Thursday, 21'st Oct 2021
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the
Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced
09:36am, Tuesday, 07'th Sep 2021
Comparisons with AGIO are from hundreds of biotech product developers viewed continually by institutional investors as capital gain sources. Values are based on how market professionals protect their
Agios To Present at September Investor Conferences
07:00am, Monday, 30'th Aug 2021
CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetic
7 Best Biotech Stocks to Buy in 2021 with Huge Upside
12:08pm, Wednesday, 25'th Aug 2021
Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
11:29am, Wednesday, 18'th Aug 2021
Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.
Agios' Rare Anemia Drug Application Under FDA Priority Review
07:03am, Wednesday, 18'th Aug 2021
The FDA has accepted Agios Pharmaceuticals Inc's (NASDAQ: AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency. Under Priority Review designation, the agen
-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --
Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress
01:41pm, Friday, 30'th Jul 2021
Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.
Amazon, Mastercard, Pinterest and More Friday Afternoon Analyst Upgrades and Downgrades
11:48am, Friday, 30'th Jul 2021
With the trading day nearly halfway over, the broad markets were pulling back into the weekend.
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2021 Results - Earnings Call Transcript
12:10am, Friday, 30'th Jul 2021
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2021 Results - Earnings Call Transcript